Marin County-based Biomarin recently made headlines after its drug to treat breast and ovarian cancer got positive enough results to move into intensive human testing. But the company's existing product line is the result of a niche strategy. Instead of vying to treat common diseases, Biomarin has so far found success in developing cures for rarer ailments.
Eric Davis, general counsel for the company, said creating drugs for "orphan diseases" - so called d... (continued)
Jun. 12, 2013
G. Eric Davis
Senior Vice President and General Counsel for BioMarin Pharmaceutical Inc. Novato
Read more about G. Eric Davis...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Already a subscriber?
Sign In